CLSN SEC-arkivering - Imunon Inc- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

LEI	529900PWLRCA840VVK89
CIK	749647

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Imunon Inc

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

June 4, 2026	EX-99.1	IMUNON Announces Up to $10 Million Cash Financing Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATI Exhibit 99.1 IMUNON Announces Up to $10 Million Cash Financing Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 4, 2026 (GLOBE NEWSWIRE) – IMUNON, Inc. (Nasdaq: IMNN), a cli
June 4, 2026	EX-10.2	SECURED PROMISSORY NOTE A-1 Exhibit 10.2 SECURED PROMISSORY NOTE A-1 Effective Date: June 2, 2026 U.S. $2,720,000.00 FOR VALUE RECEIVED, Imunon, Inc., a Delaware corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $2,720,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is eighteen (18) month
June 4, 2026	EX-10.3	SECURED PROMISSORY NOTE B Exhibit 10.3 SECURED PROMISSORY NOTE B Effective Date: June 2, 2026 U.S. $5,000,000.00 FOR VALUE RECEIVED, Imunon, Inc., a Delaware corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $5,000,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is eighteen (18) months
June 4, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 Imunon, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 Imunon, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number)
June 4, 2026	EX-10.1	Securities Purchase Agreement Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of June 2, 2026, is entered into by and between Imunon, Inc., a Delaware corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement in reliance upon
June 4, 2026	EX-3.1	CERTIFICATE OF DESIGNATION OF PREFERENCES AND RIGHTS OF SERIES A PREFERRED STOCK Imunon, Inc. a Delaware corporation Pursuant to Section 151 of the Delaware General Corporation Law Exhibit 3.1 CERTIFICATE OF DESIGNATION OF PREFERENCES AND RIGHTS OF SERIES A PREFERRED STOCK of Imunon, Inc. a Delaware corporation Pursuant to Section 151 of the Delaware General Corporation Law The undersigned, Stacy R. Lindborg, hereby certifies that: 1. She is the duly elected Chief Executive Officer of Imunon, Inc., a Delaware corporation (“Corporation”). 2. A resolution was adopted and appro
May 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Imunon, Inc. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Imunon, Inc.
May 12, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I
May 12, 2026	EX-99.1	IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed w Exhibit 99.1 IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable
May 4, 2026	EX-10.1	CHANGE IN CONTROL SEVERANCE AGREEMENT Exhibit 10.1 CHANGE IN CONTROL SEVERANCE AGREEMENT THIS CHANGE IN CONTROL SEVERANCE AGREEMENT (this “ Agreement “) is made and entered into this [ ] day of [ ] (the “ Effective Date “), by and between Imunon, Inc., a Delaware corporation (the “ Company “), and (the “ Executive “). RECITALS WHEREAS, the Executive is a key executive of the Company; WHEREAS, should the possibility of a Change in Cont
May 4, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
May 4, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2026 Imunon, Inc. (Exact nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2026 Imunon, Inc.
May 4, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. or ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC.
March 31, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex
March 31, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Imunon, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Imunon, Inc.
March 31, 2026	EX-21.1	Subsidiaries of Imunon, Inc. Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware
March 31, 2026	EX-4.8	DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED DESCRIPTION OF CAPITAL STOCK EXHIBIT 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED DESCRIPTION OF CAPITAL STOCK The following summary of the general terms and provisions of the capital stock of Imunon, Inc. (“Imunon”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Amended an
March 31, 2026	EX-99.1	IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival be Exhibit 99.1 IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvemen
March 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 IMUNON, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 IMUNON, INC.
March 23, 2026	424B5	IMUNON, INC. Up to $17,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated May 22, 2024, Prospectus Supplement dated September 3, 2024, and Prospectus Supplement dated July 22, 2025) IMUNON, INC. Up to $17,000,000 of Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated September 3, 2024, as amended and
February 5, 2026	EX-10.1	RETIREMENT AND CONSULTING AGREEMENT Exhibit 10.1 RETIREMENT AND CONSULTING AGREEMENT This Retirement and Consulting Agreement (the “Agreement”) is entered into by and between Khursheed Anwer (“Executive”) and Imunon, Inc., a Delaware corporation (the “Company”), effective as of February 4, 2026 (the “Effective Date”). 1. Retirement. (a) Executive has informed the Company of his intent to voluntarily retire on February 20, 2026, or s
February 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2026 Imunon, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2026 Imunon, Inc.
January 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 Imunon, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 Imunon, Inc.
December 31, 2025	424B5	Imunon, Inc. 330,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 1,609,114 Shares of Common Stock Warrants to Purchase up to 1,939,114 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2024) Imunon, Inc. 330,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 1,609,114 Shares of Common Stock Warrants to Purchase up to 1,939,114 Shares of Common Stock We are offering directly to a single healthcare-focused institutional investor (the “Purchaser”) 330,000 sh
December 31, 2025	EX-4.2	TO PURCHASE SHARES OF COMMON STOCK Imunon, INC. Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK Imunon, INC. Warrant Shares: Initial Exercise Date: December 31, 2025 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
December 31, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and
December 31, 2025	EX-4.1	PREFUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Initial Exercise Date: December 31, 2025 THIS PREFUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t
December 31, 2025	EX-99.1	IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules Exhibit 99.1 IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules LAWRENCEVILLE, N.J., December 30, 2025 — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional inve
December 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2025 IMUNON, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2025 IMUNON, INC.
November 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno
November 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Imunon, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Imunon, Inc.
November 13, 2025	S-8	As filed with the Securities and Exchange Commission on November 13, 2025 As filed with the Securities and Exchange Commission on November 13, 2025 Registration No.
November 13, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, p
November 13, 2025	EX-99.1	IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first fr Exhibit 99.1 IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., November 13
September 10, 2025	LETTER	LETTER September 10, 2025 Kimberly Graper Chief Financial Officer Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Imunon, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-15911 Dear Kimberly Graper: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwit
August 28, 2025	EX-99.1	IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement Exhibit 99.1 IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement LAWRENCEVILLE, N.J., August 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasda
August 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 IMUNON, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 IMUNON, INC.
August 13, 2025	CORRESP	* * * * August 13, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
August 5, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Imunon, Inc.
August 5, 2025	EX-99.1	IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient Exhibit 99.1 IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call tod
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, In
August 4, 2025	LETTER	LETTER August 4, 2025 Kimberly Graper Interim Chief Financial Officer Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Imunon, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 Filed February 27, 2025 File No. 001-15911 Dear Kimberly Graper: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the request
July 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Imunon, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Imunon, Inc.
July 28, 2025	EX-99.1	IMUNON Announces Stock Dividend Boosting Shareholder Value Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders Exhibit 99.1 IMUNON Announces Stock Dividend Boosting Shareholder Value Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that its Board of Di
July 23, 2025	EX-3.1	Amendment to the Restated Certificate of Incorporation, dated July 21, 2025 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF IMUNON, INC. Imunon, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Imunon, Inc. SECOND: This Certificate of Amendment (the “Certificate of Amendment”) amends the pro
July 23, 2025	EX-99.1	IMUNON Announces Reverse Stock Split Exhibit 99.1 IMUNON Announces Reverse Stock Split LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one (1) share of common stock for every fifteen (15) shares o
July 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 Imunon, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 Imunon, Inc.
July 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 IMUNON, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 IMUNON, INC.
July 22, 2025	424B5	IMUNON, INC. Up to $10,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated May 22, 2024 and Prospectus Supplement dated September 3, 2024) IMUNON, INC. Up to $10,000,000 of Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated September 3, 2024 (the “ATM Prospectus Supplement”), to the accompanying base
July 14, 2025	EX-10.1	IMUNON, Inc. 2018 Stock Incentive Plan, as amended as of July 11, 2025 EXHIBIT 10.1 IMUNON, INC. THE 2018 STOCK INCENTIVE PLAN AS AMENDED AS OF JULY 11, 2025 I. INTRODUCTION 1.1 Purposes. The purposes of the IMUNON, INC. 2018 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to a
July 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IMUNON, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IMUNON, INC.
July 11, 2025	EX-3.1	Amendment to the Restated Certificate of Incorporation, dated July 11, 2025 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF IMUNON, INC. Imunon, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Imunon, Inc. SECOND: This Certificate of Amendment (the “Certificate of Amendment”) amends the pro
July 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 Imunon, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 Imunon, Inc.
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Imunon, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Imunon, Inc.
June 13, 2025	424B3	IMUNON, INC. UP TO 22,027,780 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(3) Registration No. 333-287699 PROSPECTUS IMUNON, INC. UP TO 22,027,780 SHARES OF COMMON STOCK This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 22,027,780 shares of common stock, par value $0.01 per share, of Imunon, Inc. (the “Common Sto
June 13, 2025	EX-10.1	Offer Letter, dated September 20, 2022, between the Company and Kimberly Graper Exhibit 10.1
June 11, 2025	CORRESP	June 11, 2025 June 11, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Imunon, Inc. Registration Statement on Form S-1 File No. 333-287699 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), Imunon, Inc. (the “Company”) hereby requests that the Securities and Exchange Com
June 11, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. or ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC.
June 9, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 IMUNON, INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 IMUNON, INC.
June 5, 2025	LETTER	LETTER June 5, 2025 Stacy Lindborg President and Chief Executive Officer Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Imunon, Inc. Registration Statement on Form S-1 File No. 333-287699 Filed May 30, 2025 Dear Stacy Lindborg: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acce
May 30, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, pa
May 30, 2025	S-1	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No.
May 30, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 30, 2025	CORRESP	May 30, 2025 May 30, 2025 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F.
May 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 IMUNON, INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 IMUNON, INC.
May 27, 2025	EX-10.2	Form of Registration Rights Agreement. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 23, 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement,
May 27, 2025	EX-4.3	Form of Placement Agent Warrant. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 27, 2025	EX-4.1	Form of Pre-Funded Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 27, 2025	EX-4.2	Form of Common Warrant, dated May 27, 2025, incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K of the Company filed on May 27, 2025 (SEC File No. 001-15911). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 27, 2025	EX-99.1	IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants Exhibit 99.1 IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J. (May 23, 2025) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunothera
May 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 IMUNON, INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 IMUNON, INC.
May 27, 2025	EX-10.1	Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 23, 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i
May 22, 2025	RW	Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 RW 1 formrw.htm RW Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 May 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Alan Campbell Re: Imunon, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-286403 Ladies and Gentlemen: On April 4, 2025, Imunon, Inc. (the “Registrant”
May 22, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 IMUNON, INC.
May 20, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 IMUNON, INC.
May 19, 2025	EX-4.9	Form of Common Stock Purchase Warrant. Exhibit 4.9 IMUNON, INC. Warrant To Purchase Common Stock Warrant Shares: [●] Issuance Date: [●], 2025 Initial Exercise Date: [●], 2025 Imunon, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], the registered holder hereof or its permitted assigns (the “Holder”), is entitled,
May 19, 2025	S-1/A	As filed with the Securities and Exchange Commission on May 19, 2025 As filed with the Securities and Exchange Commission on May 19, 2025 Registration No.
May 19, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity Common stock,
May 19, 2025	EX-10.30	Form of Securities Purchase Agreement. Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t
May 13, 2025	EX-4.9	Form of Common Stock Purchase Warrant. Exhibit 4.9 IMUNON, INC. Warrant To Purchase Common Stock Warrant Shares: [●] Issuance Date: [●], 2025 Initial Exercise Date: [●], 2025 Imunon, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], the registered holder hereof or its permitted assigns (the “Holder”), is entitled,
May 13, 2025	EX-10.31	Form of Exchange Agreement, dated May 12, 2025. Exhibit 10.31 Exchange Agreement THIS EXCHANGE AGREEMENT (the “Agreement”) is dated as of May 12, 2025 (the “Effective Date”), by and among Imunon, Inc., a Delaware corporation (the “Company”), and each Holder identified on the signature pages hereto (each, a “Holder” and collectively, the “Holders”). WHEREAS, prior to the execution of this Agreement, the Company entered into that certain Securiti
May 13, 2025	EX-1.1	Form of Placement Agency Agreement. Exhibit 1.1 [], 2025 Imunon, Inc. Attention: Stacy R. Lindborg 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Placement Agency Agreement Dear Dr. Lindborg: Subject to the terms and conditions of this letter agreement (the “Agreement”) by and between Brookline Capital Markets, a division of Arcadia Securities, LLC, as placement agent (the “Placement Agent”), and Imunon, Inc., a Delaware cor
May 13, 2025	EX-10.30	Form of Securities Purchase Agreement. Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t
May 13, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity Common stock,
May 13, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Imunon, Inc.
May 13, 2025	S-1/A	As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No.
May 13, 2025	EX-10.1	Form of Exchange Agreement, dated May 12, 2025. Exhibit 10.1 Exchange Agreement THIS EXCHANGE AGREEMENT (the “Agreement”) is dated as of May 12, 2025 (the “Effective Date”), by and among Imunon, Inc., a Delaware corporation (the “Company”), and each Holder identified on the signature pages hereto (each, a “Holder” and collectively, the “Holders”). WHEREAS, prior to the execution of this Agreement, the Company entered into that certain Securitie
May 12, 2025	EX-99.1	IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 ac Exhibit 99.1 IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I
May 12, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Imunon, Inc.
April 4, 2025	S-1	As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.
April 4, 2025	EX-10.30	Form of Securities Purchase Agreement. Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in th
April 4, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity Common stock,
April 4, 2025	EX-4.8	Form of Pre-Funded Warrant. Exhibit 4.8 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Exercise Date: [], 2025 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
April 4, 2025	EX-4.9	Form of Common Stock Purchase Warrant. Exhibit 4.9 WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: [] Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
April 4, 2025	EX-1.1	Form of Placement Agency Agreement. Exhibit 1.1 [], 2025 Imunon, Inc. Attention: Stacy R. Lindborg 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Placement Agency Agreement Dear Dr. Lindborg: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as lead placement agent (“A.G.P.”), Brookline Capital Markets, a division of Arcadia Securities, LLC, as a co-placem
March 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 IMUNON, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 IMUNON, INC.
March 24, 2025	EX-99.1	IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of Exhibit 99.1 IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesd
March 19, 2025	DRS	CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on March 19, 2025 This draft registration statement has not been filed publicly with the Secur CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on March 19, 2025 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE C
February 27, 2025	EX-19	Insider Trading Policy Exhibit 19
February 27, 2025	EX-21.1	Subsidiaries of Imunon, Inc., incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K of the Company for the year ended December 31, 2024 (SEC File No. 001-15911). Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware
February 27, 2025	EX-99.1	IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanc Exhibit 99.1 IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 2025 Company to hold conference call t
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex
February 27, 2025	EX-4.7	Description of Securities of the Registrant, incorporated by reference to Exhibit 4.7 to the Annual Report on Form 10-K of the Company for the year ended December 31, 2024 (SEC File No. 001-15911). EXHIBIT 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED DESCRIPTION OF CAPITAL STOCK The following summary of the general terms and provisions of the capital stock of Imunon, Inc. (“Imunon”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Amended an
February 27, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Imunon, Inc.
February 10, 2025	EX-99.1	IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology Exhibit 99.1 IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunot
February 10, 2025	EX-10.1	Offer Letter of Employment between Imunon, Inc. and Douglas Faller Exhibit 10.1
February 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2025 IMUNON, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2025 IMUNON, INC.
November 27, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 IMUNON, INC.
November 14, 2024	SC 13G/A	IMNN / Imunon, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2428264d3sc13ga.htm SC 13G/A CUSIP No: 15117N602 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Imunon, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Sec
November 14, 2024	SC 13G	CLSN / Imunon Inc / Ayrton Capital LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* IMUNON, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 15117N503 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
November 7, 2024	EX-99.1	Conference call today at 11:00 a.m. ET Exhibit 99.1 IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 7, 2024 – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provide
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno
November 7, 2024	EX-10.5	Separation Agreement, dated August 9, 2024 by and between the Company and Sébastien Hazard, M.D., incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (SEC file No. 001-15911). Exhibit 10.5
November 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Imunon, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Imunon, Inc.
October 7, 2024	EX-99.1	IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Exhibit 99.1 IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) LAWRENCEVILLE, N.J. (October 7, 2024) – IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options to purchas
October 7, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 IMUNON, INC.
October 7, 2024	EX-10.1	Offer Letter of Employment, dated October 2, 2024, between Imunon, Inc. and Susan Eylward, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on October 7, 2024 (SEC File No. 001-15911). Exhibit 10.1
September 27, 2024	424B3	Imunon, Inc. 5,000,000 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933 in connection with Registration Statement No.
September 24, 2024	CORRESP	September 24, 2024 September 24, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Imunon, Inc. (the “Company”) Registration Statement Filed on Form S-1 (the “Registration Statement”) File No. 333-281834 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby re
September 20, 2024	S-1/A	As filed with the Securities and Exchange Commission on September 20, 2024 As filed with the Securities and Exchange Commission on September 20, 2024 Registration No.
September 5, 2024	LETTER	LETTER September 5, 2024 Michael H. Tardugno Executive Chairman of the Board Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Imunon, Inc. Registration Statement on Form S-1 Filed August 29, 2024 File No. 333-281834 Dear Michael H. Tardugno: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding reque
September 3, 2024	424B5	Imunon, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2024) $5,500,000 Imunon, Inc. Common Stock We have entered into an At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024, which, as amended, we refer to as the ATM Agreement, with H.C. Wainw
September 3, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 IMUNON, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Num
August 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type
August 29, 2024	S-8	As filed with the Securities and Exchange Commission on August 29, 2024 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMUNON, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 997 Lenox D
August 29, 2024	EX-FILING FEES	Calculation of Registration Fee Exhibit 107.1 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per share (“Common Stoc
August 29, 2024	S-1	As filed with the Securities and Exchange Commission on August 29, 2024 As filed with the Securities and Exchange Commission on August 29, 2024 Registration No.
August 29, 2024	EX-99.1	Form of Nonqualified Stock Option and Restricted Stock Grant Agreement for employment inducement awards, incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed on August 29, 2024 (No. 333-281833). EX-99.1 4 ex99-1.htm Exhibit 99.1 IMUNON, INC. TERMS AND CONDITIONS OF STOCK OPTION AND RESTRICTED STOCK NONQUALIFIED STOCK OPTION AND RESTRICTED STOCK GRANT AGREEMENT THIS NONQUALIFIED STOCK OPTION AND RESTICTED STOCK GRANT AGREEMENT (this “Agreement”) is made and entered into as of the day of , 202, by and between IMUNON, INC. (the “Corporation”), a Delaware corporation, and , an individual empl
August 14, 2024	EX-99.1	IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time EX-99.1 2 ex99-1.htm Exhibit 99.1 Final AUGUST 12, 2024 IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (August 14, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immuno-oncology therapy, today reported financial results for
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, In
August 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Imunon, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Imunon, Inc.
August 5, 2024	SC 13G	IMNN / Imunon, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 15117N602 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Imunon, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 15117N602 (CUSIP Number) July 30,
August 5, 2024	EX-99.I	Limited Power of Attorney EX-99.I 2 tm2420811d1ex99-i.htm EXHIBIT I CUSIP No: 15117N602 Exhibit I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands. WHEREAS, by agreement dated July 16, 2015,
August 5, 2024	EX-99.II	Joint Filing Agreement EX-99.II 3 tm2420811d1ex99-ii.htm EXHIBIT II CUSIP No: 15117N602 EXHIBIT II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Imunon, Inc., $0.01 par value per share, is bei
August 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 IMUNON, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 IMUNON, INC.
August 1, 2024	424B5	Imunon, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2024) Imunon, Inc. 5,000,000 Shares of Common Stock We are offering directly to certain purchasers 5,000,000 shares (the “Shares”) of our common stock, par value $0.01 per share. The Shares are being offered pursuant to a securities purchase agreement, dated as of July 30, 2024 (the “Pur
July 31, 2024	EX-4.1	Form of Warrant, incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K of the Company filed on July 31, 2024 (SEC File No. 001-15911). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IMUNON, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IMUNON, INC.
July 31, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of July 30, 2024, by and among the Company and each purchaser party thereto, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company, filed on July 31, 2024 (SEC File No. 001-15911). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth
July 31, 2024	EX-99.1	IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Exhibit 99.1 IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules LAWRENCEVILLE, N.J. (July 31, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IMUNON, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IMUNON, INC.
July 30, 2024	EX-99.1	IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 Exhibit 99.1 IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 ● Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in the intent-to-treat patient population compared with the standard-of-care control arm ● Overall survi
July 30, 2024	EX-99.2	Imunon, Inc. Phase 2 OVATION 2 Data Presentation Exhibit 99.2
June 13, 2024	8-K	Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 (June 12, 2024) IMUNON, INC.
May 20, 2024	LETTER	LETTER United States securities and exchange commission logo May 20, 2024 Michael Tardugno Executive Chairman of the Board Imunon, Inc.
May 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 IMUNON, INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 IMUNON, INC.
May 20, 2024	CORRESP	May 20, 2024 May 20, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Imunon, Inc. (the “Company”) Registration Statement Filed on Form S-3 (the “Registration Statement”) File No. 333-279425 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfu
May 20, 2024	EX-10.1	Retirement and Consulting Agreement, dated May 17, 2024, between Imunon, Inc. and Jeffrey Church, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on May 20, 2024 (SEC File No. 001-15911). Exhibit 10.1 RETIREMENT AND CONSULTING AGREEMENT This Retirement and Consulting Agreement (the “Agreement”) is entered into by and between Jeffrey Church (“Executive”) and Imunon, Inc., a Delaware corporation (the “Company”), effective as of May 17, 2024 (the “Effective Date”). 1. Retirement. (a) Executive has informed the Company of his intent to voluntarily retire on June 1, 2024, or such earlie
May 20, 2024	EX-10.2	Consulting Agreement, dated April 15, 2024, by and between Imunon, Inc. and Monomoy Advisors, LLC incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on May 20, 2024 (SEC File No. 001-15911). Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as April 15, 2024 (the “Effective Date”), by and between Imunon, Inc. (the “Client”) and Monomoy Advisors, LLC (“Monomoy”). The Client and Monomoy are herein sometimes referred to individually as a “Party” and collectively as the “Parties.” The Parties agree that Monomoy will be engaged on the following
May 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Carry Forward Form T
May 15, 2024	EX-4.6	Form of Indenture. Exhibit 4.6 CELSION CORPORATION and [NAME OF TRUSTEE], as Trustee INDENTURE Dated as of , 202 CROSS-REFERENCE TABLE TIA Section Indenture Section 310 (a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.10 (b) 7.08; 7.10 (b)(1) 7.10 311 (a) N.A. (b) 7.11 (c) 7.11 312 (a) N.A. (b) 2.06 (c) 10.03 313 (a) 10.03 (b) 7.06 (b)(1) 7.08 (b)(2) N.A. (c) 7.06 (d) 7.06 314 (a) 4.08; 10.04 (b) N.A. (c)(1)
May 15, 2024	EX-1.3	Amendment No. 1, dated May 15, 2024, to At the Market Offering Agreement, by and between Imunon, Inc. and H.C. Wainwright & Co. LLC, incorporated by reference to Exhibit 1.3 to the Company’s Registration Statement on Form S-3 (No. 333-279425) filed on May 15, 2024. Exhibit 1.3 May 15, 2024 Imunon, Inc. 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648 Attention: Jeffrey Church, Chief Financial Officer Re: Amendment No. 1 to At The Market Offering Agreement Dear Mr. Church: Reference is made to the At The Market Offering Agreement, dated as of May 25, 2022 (the “ATM Agreement”), between Imunon, Inc. (f/k/a Celsion Corporation) (the “Company”) and H.C. Wainw
May 15, 2024	S-3	As filed with the Securities and Exchange Commission on May 15, 2024 As filed with the Securities and Exchange Commission on May 15, 2024 Registration No.
May 13, 2024	EX-99.1	IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time Exhibit 99.1 IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (May 13, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the three mont
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I
May 13, 2024	EX-10.1	Form of Incentive Stock Option Grant Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2024 (SEC File No. 001-15911). Exhibit 10.1 SERIAL NUMBER: 2018SOP- IMUNON, INC. 2018 STOCK INCENTIVE PLAN INCENTIVE STOCK OPTION GRANT AGREEMENT THIS GRANT AGREEMENT (this “Agreement”) is made and entered into as of the day of , by and between IMUNON, INC. (the “Corporation”), a Delaware corporation, and , an individual employed by or performing services for the Corporation (“Grantee”). ARTICLE 1 GRANT OF OPTION Section 1.1 Gr
May 13, 2024	EX-10.2	Form of Restricted Stock Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2024 (SEC File No. 001-15911). Exhibit 10.2 SERIAL NUMBER: 2018RSG- IMUNON, INC 2018 STOCK INCENTIVE PLAN RESTRICTED STOCK AGREEMENT THIS STOCK AGREEMENT (this “Agreement”) is made and entered into as of the day of , by and between IMUNON, INC (the “Corporation”), a Delaware corporation, and , an individual employed by or performing services for the Corporation (“Grantee”). ARTICLE 1 GRANT OF RESTRICTED STOCK Section 1.1 Grant
May 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Imunon, Inc. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Imunon, Inc.
May 8, 2024	EX-99.1	IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy Exhibit 99.1 IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J. (May 8, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-media
May 8, 2024	EX-10.1	Employment Agreement, dated as of May 3, 2024, between the Company and Stacy Lindborg, Ph.D., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on May 8, 2024 (SEC File No. 001-15911). Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of the 3rd day of May, 2024 (the “Effective Date”), by and between Imunon, Inc., a Delaware corporation (the “Company”), and Stacy Lindborg, Ph.D., an individual (the “Executive”). WITNESSETH WHEREAS, the Company desires to retain the Executive to serve in the capacities of President
May 8, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 IMUNON, INC.
April 29, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 11, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 (April 10, 2024) Imunon, Inc.
April 11, 2024	EX-99.1	IMUNON Reports Compliance with Nasdaq Listing Requirements Exhibit 99.1 IMUNON Reports Compliance with Nasdaq Listing Requirements LAWRENCEVILLE, N.J. (April 11, 2024) – IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Sto
April 10, 2024	RW	Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 April 10, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Jason Drory Re: Imunon, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-276174 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933,
March 28, 2024	EX-97.0	Compensation Recovery Policy Exhibit 97 Imunon, Inc. Executive Officer Incentive Compensation Recovery Policy I. Purpose The Board of Directors (the “Board”) of Imunon, Inc., a Delaware corporation (the “Company”), has adopted this policy (this “Policy”) which requires the recovery of certain executive compensation in the event that the Company is required to prepare an Accounting Restatement (as defined below). References he
March 28, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Imunon, Inc.
March 28, 2024	EX-99.1	IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 10:00 a.m. Eastern Time Exhibit 99.1 IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (March 28, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31
March 28, 2024	EX-21.1	Subsidiaries of Imunon, Inc., incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K of the Company for the year ended December 31, 2023 (SEC File No. 001-15911). Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware
March 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex
March 18, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 Imunon, Inc.
March 18, 2024	EX-3.1	Amended and Restated Bylaws of the Company, effective on March 15, 2024, incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company, filed on March 18, 2024 (SEC File No. 001-15911). Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF IMUNON, INC. (Compiled and reflecting all amendments through March 15, 2024) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the corporation shall be fixed in the Certificate of Incorporation of the corporation, as amended from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The board of directors (the “Bo
March 12, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Imunon, Inc.
March 12, 2024	EX-99.1	IMUNON Announces Leadership Change Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged. Exhibit 99.1 IMUNON Announces Leadership Change Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J. (March 12, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vacci
February 9, 2024	EX-10.25	Form of Securities Purchase Agreement. Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t
February 9, 2024	EX-4.9	Form of Series B Common Stock Purchase Warrant. Exhibit 4.9 SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Issuance Date: [*] , 2024 THIS SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a
February 9, 2024	EX-4.8	Form of Series A Common Stock Purchase Warrant. Exhibit 4.8 SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Issuance Date: [*] , 2024 THIS SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a
February 9, 2024	S-1/A	As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.
February 9, 2024	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee (3) Carry Forward Fo
January 18, 2024	EX-1.1	Form of Placement Agency Agreement Exhibit 1.1 [], 2024 Imunon, Inc. Attention: Dr. Corinne Le Goff 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Placement Agency Agreement Dear Dr. Le Goff: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as lead placement agent (“A.G.P.”), Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline,”
January 18, 2024	EX-4.8	Form of Common Stock Purchase Warrant Exhibit 4.8 WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Issuance Date: [*] , 202[●] THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Origina
January 18, 2024	S-1/A	As filed with the Securities and Exchange Commission on January 17, 2024 As filed with the Securities and Exchange Commission on January 17, 2024 Registration No.
January 18, 2024	EX-10.25	Form of Securities Purchase Agreement. Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t
January 18, 2024	EX-4.7	Form of Pre-Funded Warrant Exhibit 4.7 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Exercise Date: [*], 202[●] THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
December 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 (December 26, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 (December 26, 2023) Imunon, Inc.
December 20, 2023	S-1	As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No.
December 20, 2023	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee (3) Carry Forward Fo
December 11, 2023	EX-10.1	Offer Letter of Employment between Imunon, Inc. and Sébastien Hazard Exhibit 10.1 December 7, 2023 Dr. Sébastien Hazard 7 Rangeley Rd. Winchester, MA 01890 [email protected] Dear Sébastien, I am pleased to extend to you an offer of employment with IMUNON, Inc. as Executive Vice President and Chief Medical Officer. In this capacity, you will be a member of IMUNON’s senior executive staff and will report directly to me. Your starting salary will be $18,269.23
December 11, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 IMUNON, INC.
December 11, 2023	EX-99.1	IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectiou Exhibit 99.1 IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J. (December 11, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on de
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno
November 14, 2023	EX-99.1	IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Co Exhibit 99.1 IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins Today at 10:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Imunon, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Imunon, Inc.
August 11, 2023	S-8	As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.
August 11, 2023	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Equity Common Stock Rule 457(c) and Rule 457(h) 1,030,0
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, In
August 10, 2023	EX-99.1	IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Cal Exhibit 99.1 IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (August 10, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development c
August 10, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Imunon, Inc.
June 15, 2023	EX-10.1	Imunon, Inc. 2018 Stock Incentive Plan, as amended as of June 14, 2023, incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company, filed with the Commission on June 15, 2023 (SEC File No. 001-15911). Exhibit 10.1 IMUNON, INC. 2018 STOCK INCENTIVE PLAN, AS AMENDED AS OF JUNE 14, 2023 I. INTRODUCTION 1.1 Purposes. The purposes of the IMUNON, Inc. 2018 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to adva
June 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 (June 14, 2023) IMUNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 (June 14, 2023) IMUNON, INC.
June 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 (June 14, 2023) IMUNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 (June 14, 2023) IMUNON, INC.
May 26, 2023	LETTER	LETTER United States securities and exchange commission logo May 26, 2023 Jeffrey Church Chief Financial Officer Imunon, Inc.
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Imunon, Inc. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Imunon, Inc.
May 11, 2023	EX-99.1	IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins T Exhibit 99.1 IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (May 11, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focuse
May 5, 2023	CORRESP	Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 May 5, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Vanessa Robertson/Kevin Vaughn Re: Imunon, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 30, 2023 File No. 001-15911 Ladies and Gentlemen: This letter
May 3, 2023	LETTER	LETTER United States securities and exchange commission logo May 3, 2023 Jeffrey Church Chief Financial Officer Imunon, Inc.
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 30, 2023	EX-21.1	Subsidiaries of Imunon, Inc., incorporated herein by reference to Exhibit 21.1 to the Annual Report of the Company for the year ended December 31, 2022 (SEC File No. 001-15911). Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware Celsion GmbH Switzerland
March 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex
March 30, 2023	EX-99.1	IMUNON Reports 2022 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time Exhibit 99.1 IMUNON Reports 2022 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (March 30, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2022, and
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Imunon, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Imunon, Inc.
March 30, 2023	EX-10.25	Loan Facility Agreement, dated as of June 18, 2021, by and between the Company and Silicon Valley Bank. Exhibit 10.25 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (“Bank”), and the borrower listed on Schedule I hereto (“Borrower”). The parties agree as follows: 1 LOAN AND TERMS OF PAYMENT 1.1 Term Loan. (a) Availability. Subject to the terms and conditions of this Agreement, upo
March 24, 2023	EX-3.1	Amended and Restated Certificate of Incorporation of Imunon, dated March 24, 2023, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company filed on March 24, 2023 (SEC File No. 001-15911). Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF IMUNON, INC. (Compiled and reflecting all amendments through March 22, 2023) Imunon, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Imunon, Inc. 2. The Corporation was originally incorporated
March 24, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2023 (March 22, 2023) Imunon, Inc.
February 10, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2023 (February 7, 2023) Imunon, Inc.
January 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 (December 31, 2022) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 (December 31, 2022) IMUNON, INC.
November 15, 2022	EX-99.2	Imunon, Inc. Corporate Presentation – November 2022 Exhibit 99.2
November 15, 2022	EX-99.1	IMUNON, Inc. Third Quarter 2022 Conference Call Monday, November 14, 2022 11:00 a.m. Eastern time Exhibit 99.1 IMUNON, Inc. Third Quarter 2022 Conference Call Monday, November 14, 2022 11:00 a.m. Eastern time Operator Please stand by. Good morning. My name is Marlise and I will be your operator today. At this time, I would like to welcome you to IMUNON?s third quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. Following the speak
November 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 (November 14, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 (November 14, 2022) IMUNON, INC.
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Imunon, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Imunon, Inc.
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno
November 14, 2022	EX-99.1	IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET Exhibit 99.1 IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2022) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month period
October 3, 2022	EX-99.1	Imunon Appoints James E. Dentzer to its Board of Directors CEO of Curis brings extensive biopharmaceutical financial experience to the Board Exhibit 99.1 Imunon Appoints James E. Dentzer to its Board of Directors CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J. (October 3, 2022) ? Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug development company, announces the appointment of James E. Dentzer to its Board of Directors, effective immediately. Mr. Dentzer is the chief executive off
October 3, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 (October 3, 2022) IMUNON, INC.
September 19, 2022	EX-99.1	Celsion Corporation Announces Company Name Change to Imunon, Inc. New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines Exhibiti 99.1 Celsion Corporation Announces Company Name Change to Imunon, Inc. New name reflects the evolution of the Company?s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., September 19, 2022 ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of t
September 19, 2022	EX-3.1	Certificate of Amendment, as filed with the Secretary of State of the State of Delaware, effective on September 19, 2022. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF CELSION CORPORATION Celsion Corporation (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of the Corporation is Celsion Corporation. SECOND: The original Certificate of Incorporation of the Corporation (fo
September 19, 2022	EX-3.2	Certificate of Elimination of Series A Convertible Redeemable Preferred Stock and Series B Convertible Redeemable Preferred Stock, as filed with the Secretary of State of the State of Delaware, effective on September 16, 2022. Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SERIES B CONVERTIBLE REDEEMABLE PREFERRED STOCK OF CELSION CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware Celsion Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Company?), in accordance with the provisions of
September 19, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 (September 16, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
September 19, 2022	EX-3.3	Amended and Restated Bylaws of the Company, effective on September 19, 2022, incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K of the Company, filed on September 19, 2022 (SEC File No. 001-15911). Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF IMUNON, INC. (Compiled and reflecting all amendments through September 19, 2022) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the corporation shall be fixed in the Certificate of Incorporation of the corporation, as amended from time to time (the ?Certificate of Incorporation?). 1.2 OTHER OFFICES. The board of directors (the
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSION CO
August 15, 2022	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Celsion Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock Rule 457(c) and Rule 457(h) 513,333 $ 2.
August 15, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
August 15, 2022	S-8	As filed with the Securities and Exchange Commission on August 15, 2022 As filed with the Securities and Exchange Commission on August 15, 2022 Registration No.
August 15, 2022	EX-99.1	Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT Exhibit 99.1 Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (August 15, 2022) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated i
July 19, 2022	EX-10.2	Employment Agreement between the Company and Michael H. Tardugno, effective as of July 18, 2022, incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of the Company filed with the Commission on July 19, 2022 (SEC File No. 001-15911). Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of the 18th day of July 2022 (the ?Effective Date?), by and between Celsion Corporation, a Delaware corporation (the ?Company?), and Michael H. Tardugno, an individual (the ?Executive?). WITNESSETH WHEREAS, the parties hereto previously entered into that certain Amended and Restated
July 19, 2022	EX-99.1	Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer Michael H. Tardugno appointed Executive Chairman of the Board Exhibit 99.1 Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company?s Board of Directors has appointed biopharmaceutica
July 19, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 (July 18, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
July 19, 2022	EX-99.2	Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) Exhibit 99.2 Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) LAWRENCEVILLE, N.J., July 19, 2022 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company?s Board of Directors approved the grant of (i) inducement stock options (the ?I
July 19, 2022	EX-10.1	Employment Agreement between the Company Corporation and Corinne Le Goff, effective as of July 18, 2022 incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed with the Commission on July 19, 2022 (SEC File No. 001-15911). Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of the 18th day of July 2022 (the ?Effective Date?), by and between Celsion Corporation, a Delaware corporation (the ?Company?), and Corinne Le Goff, an individual (the ?Executive?). WITNESSETH WHEREAS, the Company desires to employ the Executive to serve in the capacity as President
June 14, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 (June 13, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
May 25, 2022	424B5	Up to $7,500,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-254515 PROSPECTUS SUPPLEMENT DATED MAY 25, 2022 (To prospectus dated March 30, 2021) Up to $7,500,000 Common Stock We have entered into an At the Market Offering Agreement, dated as of May 25, 2022 (the ?ATM Agreement?) with H.C. Wainwright & Co., LLC (?Wainwright?), relating to shares of our common stock offered by this prospectus supplement a
May 25, 2022	EX-10.1	At the Market Offering Agreement, dated May 25, 2022 by and between Celsion Corporation and H.C. Wainwright & Co. LLC, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company, filed on May 25, 2022, (SEC File NO. 001-15911). Exhibit 10.1 CELSION CORPORATION Shares of Common Stock (par value $0.01 per share) At The Market Offering Agreement May 25, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Celsion Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Agent?), as follows: 1. Issuance and Sale of
May 25, 2022	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSION C
May 16, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

CLSN / Imunon Inc - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?